Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL111677 | 0.96 | POLB (0.52) | POLBPNPHPRT1P2RY2P2RY4 | |
| Phosphoramidic Acid SCHEMBL111065 | 0.92 | POLB (0.54) | POLBPNPHPRT1P2RY2P2RY4 | |
| Phosphoramidic Acid SCHEMBL112033 | 0.85 | NT5E (0.53) | HPRT1NT5ETGM2TAAR1KRAS | |
| Phosphoramidic Acid SCHEMBL109783 | 0.84 | POLB (0.50) | POLBP2RY2 | |
| Phosphoramidic Acid SCHEMBL109796 | 0.82 | NT5E (0.52) | HPRT1NT5ETGM2TAAR1KRAS | |
| SCHEMBL28094790 | 0.81 | POLB (0.59) | POLBPNPHPRT1P2RY2P2RY4 | |
| SCHEMBL30712246 | 0.81 | POLB (0.58) | POLBPNPP2RY2P2RY4P2RY6 | |
| Phosphoramidic Acid SCHEMBL2690062 | 0.81 | POLB (0.49) | POLBP2RY2 | |
| SCHEMBL29546691 | 0.80 | POLB (0.57) | POLBPNPP2RY2P2RY4P2RY6 | |
| SCHEMBL3503649 | 0.79 | POLB (0.56) | POLBPNPP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | POLB 6/4885PNP 1/4885HPRT1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.